RSS-Feed abonnieren
DOI: 10.1055/s-2007-980121
Tabakrauchen, chronisch obstruktive Lungenerkrankung und Lungenkarzinom
Smoking, Chronic Obstructive Pulmonary Disease and Lung CancerPublikationsverlauf
Publikationsdatum:
30. August 2007 (online)

Zusammenfassung
Rauchen ist der wesentliche Risikofaktor für das Auftreten der chronisch-obstruktiven Lungenerkrankung (COPD) sowie des Lungenkarzinoms. Als chronische Erkrankung ist die COPD mit erheblicher Einschränkung der Lebensqualität verbunden. Das Lungenkarzinom stellt in Deutschland bei Männern die führende und bei Frauen die dritthäufigste Krebs-Todesursache dar. Die vorliegende Übersicht vermittelt Daten zur Primärprävention beider Erkrankungen und die positiven Effekte der Tabakentwöhnung auf den Verlauf bei bestehender Diagnose. Tabakrauch führt über oxidativen Stress zu einer chronischen Entzündung, die im Mittelpunkt der Pathogenese der COPD steht. Onkogene Mutationen sowie durch Tabakrauch abgeschaltete Tumor-Suppressorgenen führen zur Entstehung eines Lungenkarzinoms. Frauen tragen im Vergleich zu Männern bei gleicher Exposition ein höheres Risiko für die Entwicklung beider Erkrankungen. Die Tabakentwöhnung ist die einzige therapeutische Maßnahme, die bei Patienten mit COPD die Exazerbationen sowie die Mortalität reduziert und zu einer nachhaltigen Besserung der Lungenfunktion führt. Aufgrund des hohen Abhängigkeitsgrades von Rauchern mit COPD müssen bei der Entwöhnung dieser Patienten multimodale Konzepte mit Pharmakotherapie und psychosozialer Intervention verfolgt werden. Bei Patienten mit Lungenkarzinom sind positive Effekte des Rauchstopps auf Körpergewicht, Performancestatus, postoperative Komplikationen und Mortalität gesichert. Entsprechend sollte die Tabakentwöhnung integraler Bestandteil der Lungenkarzinom-Therapie sein. Weitere Untersuchungen sind allerdings notwendig, um die Tabakentwöhnung in Relation zu etablierten Therapieansätzen besser einzuordnen.
Abstract
Smoking is the main risk factor for chronic obstructive pulmonary disease (COPD) and lung cancer. Being a chronic disease, COPD severely impairs the quality of life. Lung cancer is the leading cause of death among German males and the third most important cause of death among German females. This review gives data on the primary prevention of both diseases and the beneficial effects of smoking cessation following disease manifestation. Smoking-induced oxidative stress triggers a chronic inflammation which is central to the pathogenesis of COPD. Smoking causes lung cancer by oncogenic mutations as well as inhibition of tumour-supressor genes. Women have an increased risk to develop COPD and lung cancer as compared to men when exposed to the same amounts of tobacco smoke. Smoking cessation is the only treatment capable of reducing exacerbations and mortality as well as sustainedly improving lung function. The high level of nicotine dependence in COPD patients mandates an intensive smoking cessation treatment including pharmacotherapy and psychosocial intervention. In patients with lung cancer, smoking cessation has confirmed favourable effects on body weight, performance status, postoperative complications and mortality. Thus, smoking cessation should be an integral part of lung cancer treatment. Further research is needed to better delineate the effects of smoking cessation in relation to other treatment modalities.
Literatur
- 1
Consortium A.
Tobacco or health in the European Union.
European Commission.
2004;
ISBN 92-894-8219-2
p. 1-295
MissingFormLabel
- 2
Godtfredsen N S, Vestbo J, Osler M. et al .
Risk of hospital admission for COPD following smoking cessation and reduction: a Danish
population study.
Thorax.
2002;
57
967-972
MissingFormLabel
- 3
Meyer P A, Mannino D M, Redd S C. et al .
Characteristics of adults dying with COPD.
Chest.
2002;
122
2003-2008
MissingFormLabel
- 4
Calverley P M, Anderson J A, Celli B. et al .
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary
disease.
N Engl J Med.
2007;
356
775-789
MissingFormLabel
- 5
Shahab L, Jarvis M J, Britton J. et al .
Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary
disease in a nationally representative population sample.
Thorax.
2006;
61
1043-1047
MissingFormLabel
- 6
Wedzicha J A, Donaldson G C.
Exacerbations of chronic obstructive pulmonary disease.
Respir Care.
2003;
48
1204-1213
discussion: 1213-1215
MissingFormLabel
- 7
Lundback B, Lindberg A, Lindstrom M. et al .
Not 15 but 50 % of smokers develop COPD? - Report from the Obstructive Lung Disease
in Northern Sweden Studies.
Respir Med.
2003;
97
115-122
MissingFormLabel
- 8
de Marco R, Accordini S, Cerveri I. et al .
An international survey of chronic obstructive pulmonary disease in young adults according
to GOLD stages.
Thorax.
2004;
59
120-125
MissingFormLabel
- 9
Ben-Zaken Cohen S, Pare P D, Man S FP. et al .
The Growing Burden of Chronic Obstructive Pulmonary Disease and Lung Cancer in Women:
Examining Sex Differences in Cigarette Smoke Metabolism. 10.1164/rccm.200611 - 1655PP.
Am J Respir Crit Care Med.
2007;
176
113-120
MissingFormLabel
- 10 Society E R. Lifting the smoke screen - 10 reasons for a smoke free Europe. Brussels: European Respiratory Society: B-1000 2006: p. 28ff
MissingFormLabel
- 11
Jaakkola M S, Jaakkola J J.
Impact of smoke-free workplace legislation on exposures and health: possibilities
for prevention.
Eur Respir J.
2006;
28
397-408
MissingFormLabel
- 12
Kerstjens H A, Rijcken B, Schouten J P. et al .
Decline of FEV1 by age and smoking status: facts, figures, and fallacies.
Thorax.
1997;
52
820-827
MissingFormLabel
- 13
Gold D R, Wang X, Wypij D. et al .
Effects of cigarette smoking on lung function in adolescent boys and girls.
N Engl J Med.
1996;
335
931-937
MissingFormLabel
- 14
Sherrill D L, Lebowitz M D, Knudson R J. et al .
Smoking and symptom effects on the curves of lung function growth and decline.
Am Rev Respir Dis.
1991;
144
17-22
MissingFormLabel
- 15
Fletcher C, Peto R.
The natural history of chronic airflow obstruction.
Br Med J.
1977;
1
1645-1648
MissingFormLabel
- 16
Tashkin D P, Detels R, Simmons M. et al .
The UCLA population studies of chronic obstructive respiratory disease: XI. Impact
of air pollution and smoking on annual change in forced expiratory volume in one second.
Am J Respir Crit Care Med.
1994;
149
1209-1217
MissingFormLabel
- 17
Kemeny D M, Vyas B, Vukmanovic-Stejic M. et al .
CD8(+) T cell subsets and chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1999;
160
S33-37
MissingFormLabel
- 18
Stanescu D, Sanna A, Veriter C. et al .
Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils.
Thorax.
1996;
51
267-271
MissingFormLabel
- 19
Hautamaki R D, Kobayashi D K, Senior R M. et al .
Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice.
Science.
1997;
277
2002-2004
MissingFormLabel
- 20
Marui N, Offermann M K, Swerlick R. et al .
Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated
through an antioxidant-sensitive mechanism in human vascular endothelial cells.
J Clin Invest.
1993;
92
1866-1874
MissingFormLabel
- 21
Shapiro S D.
The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later.
Proc Assoc Am Physicians.
1995;
107
346-352
MissingFormLabel
- 22
Anthonisen N R, Connett J E, Kiley J P. et al .
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator
on the rate of decline of FEV1. The Lung Health Study.
Jama.
1994;
272
1497-1505
MissingFormLabel
- 23
Molfino N A.
Genetics of COPD.
Chest.
2004;
125
1929-1940
MissingFormLabel
- 24
He J Q, Ruan J, Connett J E. et al .
Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function
in smokers.
Am J Respir Crit Care Med.
2002;
166
323-328
MissingFormLabel
- 25
Hogg J C.
Pathophysiology of airflow limitation in chronic obstructive pulmonary disease.
Lancet.
2004;
364
709-721
MissingFormLabel
- 26
Barnes P J, Shapiro S D, Pauwels R A.
Chronic obstructive pulmonary disease: molecular and cellular mechanisms.
Eur Respir J.
2003;
22
672-688
MissingFormLabel
- 27
Wouters E F.
Chronic obstructive pulmonary disease. 5: systemic effects of COPD.
Thorax.
2002;
57
1067-1070
MissingFormLabel
- 28
Reid M B.
COPD as a muscle disease.
Am J Respir Crit Care Med.
2001;
164
1101-1102
MissingFormLabel
- 29
Andreas S, Anker S D, Scanlon P D. et al .
Neurohumoral activation as a link to systemic manifestation of chronic lung disease.
Chest.
2005;
128
3618-3624
MissingFormLabel
- 30
Narkiewicz K, Borne P J van de, Hausberg M. et al .
Cigarette smoking increases sympathetic outflow in humans.
Circulation.
1998;
98
528-534
MissingFormLabel
- 31
Scanlon P D, Connett J E, Waller L A. et al .
Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary
disease. The Lung Health Study.
Am J Respir Crit Care Med.
2000;
161
381-390
MissingFormLabel
- 32
Willemse B W, Postma D S, Timens W. et al .
The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness
and inflammation.
Eur Respir J.
2004;
23
464-476
MissingFormLabel
- 33
Anthonisen N R, Skeans M A, Wise R A. et al .
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized
clinical trial.
Ann Intern Med.
2005;
142
233-239
MissingFormLabel
- 34
Raupach T, Nowak D, Hering T. et al .
Smoking and pulmonary diseases, positive effects of smoking cessation.
Pneumologie.
2007;
61
11-14
MissingFormLabel
- 35 Meer R M van der, Wagena E J, Ostelo R WJG. et al .Smoking cessation for chronic obstructive pulmonary disease (Cochrane Review). In The Cochrane Library. Ltd.: Chichester, UK: John Wiley & Sons 2004
MissingFormLabel
- 36
Tashkin D, Kanner R, Bailey W. et al .
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind,
placebo-controlled, randomised trial.
Lancet.
2001;
357
1571-1575
MissingFormLabel
- 37
Wagena E J, Zeegers M P, Schayck C P van. et al .
Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive
pulmonary disease.
Drug Saf.
2003;
26
381-403
MissingFormLabel
- 38
Simmons M S, Connett J E, Nides M A. et al .
Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study.
Eur Respir J.
2005;
25
1011-1017
MissingFormLabel
- 39
Lacasse Y, LaForge J, Maltais F.
Got a match? Home oxygen therapy in current smokers.
Thorax.
2006;
61
374-375
MissingFormLabel
- 40 Weißbuch Lunge 2005, ed. N. Konietzko .Stuttgart: Georg Thieme Verlag 2005
MissingFormLabel
- 41
Parrott S, Godfrey C, Raw M. et al .
Guidance for commissioners on the cost effectiveness of smoking cessation interventions.
Health Educational Authority.
Thorax.
1998;
53 Suppl 5 Pt 2
S1-38
MissingFormLabel
- 42
Peto R, Darby S, Deo H. et al .
Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national
statistics with two case-control studies.
Bmj.
2000;
321
323-329
MissingFormLabel
- 43 The Health Consequences of Smoking: A Report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention,
National Center for Chronic Disease Prevention and Health Promotion. Atlanta, GA: Office on Smoking and Health 2004
MissingFormLabel
- 44
Zhou W, Heist R S, Liu G. et al .
Smoking cessation before diagnosis and survival in early stage non-small cell lung
cancer patients.
Lung Cancer.
2006;
53
375-380
MissingFormLabel
- 45
Tsao A S, Liu D, Lee J J. et al .
Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.
Cancer.
2006;
106
2428-2436
MissingFormLabel
- 46
Thomas L, Doyle L A, Edelman M J.
Lung cancer in women: emerging differences in epidemiology, biology, and therapy.
Chest.
2005;
128
370-381
MissingFormLabel
- 47 Keil U, Becher H, Heidrich J. et al .Passivrauchbedingte Morbidität und Mortalität in Deutschland. In: Passivrauchen - ein unterschätztes Gesundheitsrisiko. Heidelberg: Deutsches Krebsforschungszentrum 2005
MissingFormLabel
- 48
Hackshaw A K, Law M R, Wald N J.
The accumulated evidence on lung cancer and environmental tobacco smoke.
Bmj.
1997;
315
980-988
MissingFormLabel
- 49
Tokuhata G K, Lilienfeld A M.
Familial aggregation of lung cancer in humans.
J Natl Cancer Inst.
1963;
30
289-312
MissingFormLabel
- 50
Sanderson Cox L, Patten C A, Ebbert J O. et al .
Tobacco use outcomes among patients with lung cancer treated for nicotine dependence.
J Clin Oncol.
2002;
20
3461-3469
MissingFormLabel
- 51
Dresler C M.
Is it more important to quit smoking than which chemotherapy is used?.
Lung Cancer.
2003;
39
119-124
MissingFormLabel
- 52
Gritz E R, Dresler C, Sarna L.
Smoking, the missing drug interaction in clinical trials: ignoring the obvious.
Cancer Epidemiol Biomarkers Prev.
2005;
14
2287-2293
MissingFormLabel
- 53
Vaporciyan A A, Merriman K W, Ece F. et al .
Incidence of major pulmonary morbidity after pneumonectomy: association with timing
of smoking cessation.
Ann Thorac Surg.
2002;
73
420-425; discussion: 425 - 426
MissingFormLabel
- 54
Moller A M, Pedersen T, Villebro N. et al .
A study of the impact of long-term tobacco smoking on postoperative intensive care
admission.
Anaesthesia.
2003;
58
55-59
MissingFormLabel
- 55
Moller A M, Villebro N, Pedersen T. et al .
Effect of preoperative smoking intervention on postoperative complications: a randomised
clinical trial.
Lancet.
2002;
359
114-117
MissingFormLabel
- 56
Baser S, Shannon V R, Eapen G A. et al .
Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect
on performance status.
Chest.
2006;
130
1784-1790
MissingFormLabel
- 57
Tammemagi C M, Neslund-Dudas C, Simoff M. et al .
In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity,
which in turn predicts treatment and survival.
J Clin Epidemiol.
2004;
57
597-609
MissingFormLabel
- 58
Toh C K, Wong E H, Lim W T. et al .
The impact of smoking status on the behavior and survival outcome of patients with
advanced non-small cell lung cancer: a retrospective analysis.
Chest.
2004;
126
1750-1756
MissingFormLabel
- 59
Hamilton M, Wolf J L, Rusk J, Beard S E. et al .
Effects of smoking on the pharmacokinetics of erlotinib.
Clin Cancer Res.
2006;
12
2166-2171
MissingFormLabel
- 60
Buccheri G, Ferrigno D.
Importance of weight loss definition in the prognostic evaluation of non-small-cell
lung cancer.
Lung Cancer.
2001;
34
433-440
MissingFormLabel
- 61
Issell B F, Valdivieso M, Hersh E M. et al .
Combination chemoimmunotherapy for extensive non-oat cell lung cancer.
Cancer Treat Rep.
1978;
62
1059-1063
MissingFormLabel
- 62
Matthews N E, Adams M A, Maxwell L R. et al .
Nitric oxide-mediated regulation of chemosensitivity in cancer cells.
J Natl Cancer Inst.
2001;
93
1879-1885
MissingFormLabel
- 63
Dasgupta P, Kinkade R, Joshi B. et al .
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP
and survivin.
Proc Natl Acad Sci USA.
2006;
103
6332-6337
MissingFormLabel
- 64
Fox J L, Rosenzweig K E, Ostroff J S.
The effect of smoking status on survival following radiation therapy for non-small
cell lung cancer.
Lung Cancer.
2004;
44
287-293
MissingFormLabel
- 65
Videtic G M, Stitt L W, Dar A R. et al .
Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for
limited-stage small-cell lung cancer is associated with decreased survival.
J Clin Oncol.
2003;
21
1544-1549
MissingFormLabel
- 66
Sarihan S, Ercan I, Saran A. et al .
Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy.
Cancer Detect Prev.
2005;
29
181-188
MissingFormLabel
- 67
Monson J M, Stark P, Reilly J J. et al .
Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy
for lung carcinoma.
Cancer.
1998;
82
842-850
MissingFormLabel
- 68
Mehta V.
Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary
function, prediction, and prevention.
Int J Radiat Oncol Biol Phys.
2005;
63
5-24
MissingFormLabel
- 69
Tucker M A, Murray N, Shaw E G. et al .
Second primary cancers related to smoking and treatment of small-cell lung cancer.
Lung Cancer Working Cadre.
J Natl Cancer Inst.
1997;
89
1782-1788
MissingFormLabel
- 70
Richardson G E, Tucker M A, Venzon D J. et al .
Smoking cessation after successful treatment of small-cell lung cancer is associated
with fewer smoking-related second primary cancers.
Ann Intern Med.
1993;
119
383-390
MissingFormLabel
- 71
Ruff L K, Volmer T, Nowak D. et al .
The economic impact of smoking in Germany.
Eur Respir J.
2000;
16
385-390
MissingFormLabel
Prof. Dr. med. Stefan Andreas
Lungenfachklinik Immenhausen
Robert-Koch-Straße 3
34376 Immenhausen
eMail: sandreas@lungenfachklinik-immenhausen.de